• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Languid Uptake of Ceftazidime-Avibactam for Carbapenem-Resistant Gram-Negative Infections and Continued Reliance on Polymyxins.

作者信息

Satlin Michael J

机构信息

Division of Infectious Diseases, Department of Medicine, Weill Cornell Medicine, New York, New York, USA.

出版信息

Clin Infect Dis. 2021 Feb 16;72(4):622-625. doi: 10.1093/cid/ciaa065.

DOI:10.1093/cid/ciaa065
PMID:32107528
Abstract
摘要

相似文献

1
Languid Uptake of Ceftazidime-Avibactam for Carbapenem-Resistant Gram-Negative Infections and Continued Reliance on Polymyxins.头孢他啶-阿维巴坦对碳青霉烯类耐药革兰阴性菌感染的缓慢吸收及对多黏菌素的持续依赖
Clin Infect Dis. 2021 Feb 16;72(4):622-625. doi: 10.1093/cid/ciaa065.
2
Efficacy of ceftazidime/avibactam in monotherapy or combination therapy against carbapenem-resistant Gram-negative bacteria: A meta-analysis.头孢他啶/阿维巴坦单药或联合治疗对碳青霉烯类耐药革兰氏阴性菌的疗效：一项荟萃分析。
Int J Antimicrob Agents. 2019 Dec;54(6):735-740. doi: 10.1016/j.ijantimicag.2019.08.025. Epub 2019 Aug 31.
3
Pharmacoepidemiology of Ceftazidime-Avibactam Use: A Retrospective Cohort Analysis of 210 US Hospitals.头孢他啶-阿维巴坦的药物流行病学：210 家美国医院的回顾性队列分析。
Clin Infect Dis. 2021 Feb 16;72(4):611-621. doi: 10.1093/cid/ciaa061.
4
Meropenem-Vaborbactam versus Ceftazidime-Avibactam for Treatment of Carbapenem-Resistant Infections.美罗培南-维巴坦与头孢他啶-阿维巴坦治疗碳青霉烯类耐药感染。
Antimicrob Agents Chemother. 2020 Apr 21;64(5). doi: 10.1128/AAC.02313-19.
5
Carbapenem-resistant Escherichia coli resistant to ceftazidime-avibactam: The need for a commercially available testing product.对头孢他啶-阿维巴坦耐药的耐碳青霉烯类大肠杆菌：对市售检测产品的需求。
Am J Health Syst Pharm. 2016 Jul 15;73(14):1029-30. doi: 10.2146/ajhp160041.
6
Clinical experience with ceftazidime/avibactam for treatment of antibiotic-resistant organisms other than Klebsiella pneumoniae.治疗除肺炎克雷伯菌以外的耐药菌的头孢他啶/阿维巴坦的临床经验。
Int J Antimicrob Agents. 2018 Apr;51(4):629-635. doi: 10.1016/j.ijantimicag.2018.01.016. Epub 2018 Feb 2.
7
Multicenter Study of Outcomes with Ceftazidime-Avibactam in Patients with Carbapenem-Resistant Enterobacteriaceae Infections.头孢他啶-阿维巴坦治疗耐碳青霉烯类肠杆菌科细菌感染患者结局的多中心研究
Antimicrob Agents Chemother. 2017 Jun 27;61(7). doi: 10.1128/AAC.00449-17. Print 2017 Jul.
8
Colistin Versus Ceftazidime-Avibactam in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae.多黏菌素与头孢他啶-阿维巴坦治疗碳青霉烯类耐药肠杆菌科细菌感染。
Clin Infect Dis. 2018 Jan 6;66(2):163-171. doi: 10.1093/cid/cix783.
9
Ceftazidime-Avibactam: A Review in the Treatment of Serious Gram-Negative Bacterial Infections.头孢他啶-阿维巴坦：治疗严重革兰氏阴性细菌感染的综述。
Drugs. 2018 Apr;78(6):675-692. doi: 10.1007/s40265-018-0902-x.
10
Ceftazidime-Avibactam as Salvage Therapy for Infections Caused by Coresistant to Carbapenems and Polymyxins.头孢他啶-阿维巴坦作为治疗对碳青霉烯类和多黏菌素类耐药的感染的补救疗法。
Antimicrob Agents Chemother. 2019 Sep 23;63(10). doi: 10.1128/AAC.00528-19. Print 2019 Oct.

引用本文的文献

1
Molecular characteristics and antibiotic resistance mechanisms of multidrug-resistant Pseudomonas aeruginosa in Nanning, China.中国南宁地区多重耐药铜绿假单胞菌的分子特征及耐药机制。
BMC Microbiol. 2024 Nov 15;24(1):478. doi: 10.1186/s12866-024-03640-7.
2
Risk Factors and Outcomes of Patients with Carbapenem-Resistant Bloodstream Infection.耐碳青霉烯类血流感染患者的危险因素及预后
Infect Drug Resist. 2023 Jan 19;16:337-346. doi: 10.2147/IDR.S396428. eCollection 2023.
3
Epidemiology, Mechanisms of Resistance and Treatment Algorithm for Infections Due to Carbapenem-Resistant Gram-Negative Bacteria: An Expert Panel Opinion.
耐碳青霉烯类革兰阴性菌感染的流行病学、耐药机制及治疗方案：专家小组意见
Antibiotics (Basel). 2022 Sep 17;11(9):1263. doi: 10.3390/antibiotics11091263.
4
Early and Appropriate Use of Ceftazidime-Avibactam in the Management of Multidrug-Resistant Gram-Negative Bacterial Infections in the Indian Scenario.在印度背景下，早期且合理使用头孢他啶-阿维巴坦治疗多重耐药革兰氏阴性菌感染
Cureus. 2022 Aug 22;14(8):e28283. doi: 10.7759/cureus.28283. eCollection 2022 Aug.
5
The Role of Colistin in the Era of New β-Lactam/β-Lactamase Inhibitor Combinations.黏菌素在新型β-内酰胺/β-内酰胺酶抑制剂联合应用时代的作用
Antibiotics (Basel). 2022 Feb 20;11(2):277. doi: 10.3390/antibiotics11020277.
6
Current and future perspectives in the treatment of multidrug-resistant Gram-negative infections.当前和未来治疗多重耐药革兰氏阴性感染的观点。
J Antimicrob Chemother. 2021 Nov 22;76(Suppl 4):iv23-iv37. doi: 10.1093/jac/dkab352.
7
Cost Analysis of New Antibiotics to Treat Multidrug-Resistant Bacterial Infections: Mind the Gap.治疗多重耐药细菌感染的新型抗生素成本分析：注意差距。
Infect Dis Ther. 2021 Mar;10(1):621-630. doi: 10.1007/s40121-021-00412-y. Epub 2021 Feb 13.
8
A First Draft of the History of Treating Coronavirus Disease 2019: Use of Repurposed Medications in United States Hospitals.《2019冠状病毒病治疗史初稿：美国医院中旧药新用情况》
Open Forum Infect Dis. 2020 Dec 15;8(2):ofaa617. doi: 10.1093/ofid/ofaa617. eCollection 2021 Feb.